Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies
Authors
Keywords
-
Journal
Current Oncology Reports
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-20
DOI
10.1007/s11912-023-01458-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Addition of Peptide Receptor Radiotherapy to Immune Checkpoint Inhibition Therapy Improves Outcomes in Neuroendocrine Tumors
- (2023) Shadi A. Esfahani et al. JOURNAL OF NUCLEAR MEDICINE
- Prostate Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer
- (2022) Beshara Sheehan et al. CLINICAL CANCER RESEARCH
- Correction to: In vitro dose effect relationships of actinium‑225‑ and lutetium‑177‑labeled PSMA‑I&T
- (2022) Eline A. M. Ruigrok et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC
- (2022) Florian Rosar et al. Cancers
- Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [177Lu]Lu-PSMA-617 Radioligand Therapy in mCRPC Patients with Imminent Treatment Failure—Preliminary Evidence of Pilot Experience
- (2022) Florian Rosar et al. Cancers
- Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment
- (2022) Eline Ruigrok et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).
- (2022) Shahneen Sandhu et al. JOURNAL OF CLINICAL ONCOLOGY
- [68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy.
- (2022) Phillip Kuo et al. JOURNAL OF CLINICAL ONCOLOGY
- PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
- (2022) James P Buteau et al. LANCET ONCOLOGY
- The potential of PARP inhibitors in targeted cancer therapy and immunotherapy
- (2022) Jaromir Hunia et al. Frontiers in Molecular Biosciences
- Cytoplasmic localization of prostate-specific membrane antigen inhibitors may confer advantages for targeted cancer therapies
- (2021) Jessica Matthias et al. CANCER RESEARCH
- [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
- (2021) Michael S Hofman et al. LANCET
- Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
- (2021) Florian Rosar et al. Pharmaceutics
- ENZA‐p trial protocol: a randomized phase II trial using prostate‐specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration‐resistant prostate cancer treated with enzalutamide (ANZUP 1901)
- (2021) Louise Emmett et al. BJU INTERNATIONAL
- Global experience with PSMA-based alpha therapy in prostate cancer
- (2021) Mike M. Sathekge et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
- (2021) Magdalena Staniszewska et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immunogenic priming with 177Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): A phase 1b study.
- (2021) Rahul Raj Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- 177Lutetium PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castrate-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial
- (2021) Sarennya Pathmanandavel et al. JOURNAL OF NUCLEAR MEDICINE
- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
- (2021) Oliver Sartor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined 177 Lu‐PSMA‐617 PRLT and abiraterone acetate versus 177 Lu‐PSMA‐617 PRLT monotherapy in metastatic castration‐resistant prostate cancer: An observational study comparing the response and durability
- (2021) Sonam Suman et al. PROSTATE
- Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade
- (2021) Ravi B. Patel et al. Science Translational Medicine
- New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide
- (2020) Florian Rosar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer
- (2020) Johannes Czernin et al. JOURNAL OF NUCLEAR MEDICINE
- Phase I trial of docetaxel plus lutetium-177-labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer
- (2020) Jaspreet S. Batra et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- First clinical results for PSMA targeted alpha therapy using 225Ac-PSMA-I&T in advanced mCRPC patients
- (2020) Mathias Johannes Zacherl et al. JOURNAL OF NUCLEAR MEDICINE
- Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA
- (2020) Benedikt Feuerecker et al. EUROPEAN UROLOGY
- The Radiobiology of Radiopharmaceuticals
- (2020) Zachary S. Morris et al. SEMINARS IN RADIATION ONCOLOGY
- PREDICTORS OF OVERALL AND DISEASE FREE SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS RECEIVING 225Ac-PSMA-617 RADIOLIGAND THERAPY
- (2019) Mike Sathekge et al. JOURNAL OF NUCLEAR MEDICINE
- Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
- (2019) Alec Paschalis et al. EUROPEAN UROLOGY
- Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute
- (2019) Cristina Müller et al. Pharmaceutics
- 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
- (2019) Fadi Khreish et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
- (2019) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells
- (2018) Benedikt Kranzbühler et al. PROSTATE
- Rapid modulation of PSMA expression by Androgen deprivation: Serial 68Ga PSMA-11 PET in men with hormone sensitive and castrate resistant prostate cancer commencing androgen blockade.
- (2018) Louise M Emmett et al. JOURNAL OF NUCLEAR MEDICINE
- Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
- (2018) Katharina Lückerath et al. EJNMMI Research
- German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
- (2016) Kambiz Rahbar et al. JOURNAL OF NUCLEAR MEDICINE
- Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer
- (2015) M. Bene ova et al. JOURNAL OF NUCLEAR MEDICINE
- DNA Double Strand Breaks as Predictor of Efficacy of the Alpha-Particle Emitter Ac-225 and the Electron Emitter Lu-177 for Somatostatin Receptor Targeted Radiotherapy
- (2014) Franziska Graf et al. PLoS One
- Mammalian Base Excision Repair: the Forgotten Archangel
- (2013) Grigory L. Dianov et al. NUCLEIC ACIDS RESEARCH
- Cytotoxic effects of the novel isoflavone, phenoxodiol, on prostate cancer cell lines
- (2012) Simon Mahoney et al. JOURNAL OF BIOSCIENCES
- Therapeutic Radionuclides: Biophysical and Radiobiologic Principles
- (2008) Amin I. Kassis SEMINARS IN NUCLEAR MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now